News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Astellas Release: Exploratory Analysis Of The Phase I/II CHRYSALIS Study Of Gilteritinib Demonstrates First Molecular Response To FLT3 Inhibitor In Acute Myeloid Leukemia
June 6, 2017
|
3 min read
Twitter
LinkedIn
Facebook
Email
Print
• Maryland Jobs
• Washington Jobs
View More Jobs
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase I
Phase II
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Regulatory
Novo Nordisk Snags Kidney Disease Expansion for Ozempic in Europe
December 12, 2024
·
1 min read
·
Kate Goodwin
Phase III
Pfizer’s Ibrance Improves Survival in New Breast Cancer Indication
December 12, 2024
·
1 min read
·
Annalee Armstrong
Cardiovascular disease
Keros Suspends Two Arms of Hypertension Study After Reports of Pericardial Effusion
December 12, 2024
·
2 min read
·
Tristan Manalac
Prostate cancer
Candel Stock Skyrockets on Promising Phase III Prostate Cancer Data
December 12, 2024
·
3 min read
·
Tristan Manalac
